Charles River Buys Singapore's BRASS For Asia Expansion
This article was originally published in PharmAsia News
Singapore's BRASS, maker of biopharmaceutical and medical products, has been acquired by Charles River Laboratories of the U.S. for an undisclosed amount.
You may also be interested in...
ECHA Committee Stops Short Of Advising Derogation Or Deadline Extension For Cosmetic Microplastic Ban
Uncertainties related to leave-on cosmetics’ microplastic releases to the environment, and the costs industry would face in removing microplastic from such products, “do not allow for SEAC to conclude whether other options would be more appropriate than a ban,” the European Chemicals Agency’s Socio-Economic Analysis Committee says in a 1 July draft opinion.
US FDA could revoke orphan designation or exclusivity if cost recovery requirements were not satisfied under bill unanimously passed by the House Energy and Commerce Committee.
Officials explain how remote record reviews, site transfers and other factors can green-light approvals of drugs and biologics.